Neogen Corporation Marketable Securities, Unrealized Gain (Loss)
Neogen Corporation (NEOG) reported Marketable Securities, Unrealized Gain (Loss) of $300.00 thousand for the 12-month period ending 2024-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-07-30
- Neogen Corporation marketable securities, unrealized gain (loss) for the quarter ending 2024-05-31 was $10.00K, a 94.65% decline year-over-year.
- Neogen Corporation marketable securities, unrealized gain (loss) for the quarter ending 2024-02-29 was $24.00K, a 91.49% decline year-over-year.
- Neogen Corporation marketable securities, unrealized gain (loss) for the quarter ending 2023-11-30 was $84.00K, a 82.61% increase year-over-year.
- Neogen Corporation marketable securities, unrealized gain (loss) for the quarter ending 2023-08-31 was $183.00K.
- Neogen Corporation marketable securities, unrealized gain (loss) for fiscal 2024 was $300.00K, a 22.88% decline from fiscal 2023.
- Neogen Corporation marketable securities, unrealized gain (loss) for fiscal 2023 was $389.00K.
- Neogen Corporation marketable securities, unrealized gain (loss) for fiscal 2022 was -$728.00K.
- Neogen Corporation marketable securities, unrealized gain (loss) for fiscal 2021 was -$80.00K, a 162.99% decline from fiscal 2020.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2024-05-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $34.00K derived: sum of 2 quarters · filed 2026-07-30 | $118.00K derived: sum of 3 quarters · filed 2026-07-30 | $300.00K 10-K · filed 2026-07-30 | $293.00K 10-K · filed 2024-07-30 |
| 2024-02-29 | $24.00K 10-Q · filed 2025-04-09 | $108.00K derived: sum of 2 quarters · filed 2025-04-09 | $290.00K 10-Q · filed 2025-04-09 | $478.00K derived: sum of 4 quarters · filed 2025-07-30 | |
| 2023-11-30 | $84.00K 10-Q · filed 2025-01-15 | $267.00K 10-Q · filed 2025-01-15 | $454.00K derived: sum of 3 quarters · filed 2025-07-30 | $736.00K derived: sum of 4 quarters · filed 2025-07-30 | |
| 2023-08-31 | $183.00K 10-Q · filed 2024-10-10 | $370.00K derived: sum of 2 quarters · filed 2025-07-30 | $652.00K derived: sum of 3 quarters · filed 2025-07-30 | $698.00K derived: sum of 4 quarters · filed 2025-07-30 | |
| 2023-05-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $469.00K derived: sum of 2 quarters · filed 2025-07-30 | $515.00K derived: sum of 3 quarters · filed 2025-07-30 | $389.00K 10-K · filed 2025-07-30 | |
| 2023-02-28 | $282.00K 10-Q · filed 2024-04-09 | $328.00K derived: sum of 2 quarters · filed 2024-04-09 | $202.00K 10-Q · filed 2024-04-09 | ||
| 2022-11-30 | $46.00K 10-Q · filed 2024-01-09 | $80.00K 10-Q · filed 2024-01-09 | |||
| 2022-08-31 | -$126.00K 10-Q · filed 2023-10-10 | ||||
| 2022-05-31 | -$728.00K 10-K · filed 2024-07-30 | ||||
| 2021-05-31 | -$80.00K 10-K · filed 2023-08-15 | ||||
| 2020-05-31 | $127.00K 10-K · filed 2022-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |